Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014

Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014

ID: 317979

(Thomson Reuters ONE) -




ORION CORPORATION        STOCK EXCHANGE RELEASE 19 NOVEMBER 2013 at 12:10 p.m.
EET


The following change has been made in the responsibility areas of Orion Group
Executive Management Board as of 1 January 2014:

Mr. Markku Huhta-Koivisto, Senior Vice President responsible for Specialty
Products and Fermion business divisions and Dr. Liisa Hurme, Senior Vice
President responsible for Proprietary Products business division will exchange
their responsibility areas. Thus, as of 1 January 2014, Markku Huhta-Koivisto,
Senior Vice President, will be responsible for Proprietary Products business
division, and Liisa Hurme, Senior Vice President, will be responsible for
Specialty Products and Fermion business divisions.

They both continue to be members of the Orion Group Executive Management Board
as previously.

Timo Lappalainen, President and CEO, says:

"I am pleased that we can develop the Executive Management Board's operations in
a flexible way by this exchange of responsibility areas. I believe that the
change will give, not only a good possibility for Liisa and Markku for job
rotation, but also that it will bring positive effects for the whole Executive
Management Board and the company."



Orion Corporation



Timo Lappalainen     Olli Huotari
President and CEO SVP, Corporate Functions



Contact person:
Timo Lappalainen, President and CEO, phone: +358 50 966 3692




Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients




and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Orion Oyj via Thomson Reuters ONE
[HUG#1744144]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 19.11.2013 - 11:11 Uhr
Sprache: Deutsch
News-ID 317979
Anzahl Zeichen: 3033

contact information:
Town:

Espoo



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 234 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014"
steht unter der journalistisch-redaktionellen Verantwortung von

Orion Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Orion Oyj



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z